Clinical Trials Logo

Autistic Disorder clinical trials

View clinical trials related to Autistic Disorder.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06228157 Withdrawn - Autistic Disorder Clinical Trials

Efficacy of Stellate Ganglion Block in Children With Autistic Disorder

SGB-gudu
Start date: February 5, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to explore efficacy of stellate ganglion block Children with Autistic Disorder. The main question it aims to answer is: Can stellate ganglion block improve the Autistic Disorder in children? Children with Autistic Disorder will be divided into the control group and experimental group evenly. All the patients were provided with routine therapy, while the patients in the experimental group were given stellate ganglion block. The Childhood Autism Rating Scale of the two groups of patients before and after treatment are evaluated.

NCT ID: NCT05465148 Withdrawn - Clinical trials for Autism Spectrum Disorder

Microbiome Determinants of Neurological and Gastrointestinal Symptoms of Autism Spectrum Disorder (ASD)

Start date: May 14, 2022
Phase:
Study type: Observational

This observational study aims to identify human microbiome determinants of the symptoms associate with ASD as well as identify the human microbiome determinants of the success of FMT (fecal matter transplant) therapy and to develop a statistical model that can improve FMT donor-recipient matching. Participants are recruited through NovelBiome only, this study will NOT utilize other clinical sites.

NCT ID: NCT05413187 Withdrawn - Autistic Disorder Clinical Trials

A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder

Start date: September 1, 2020
Phase: Phase 2
Study type: Interventional

This single center, double-blinded, randomized, placebo-controlled crossover trial will assess the efficacy and safety of extraction of cannabis flowers dissolved in olive oil (30% CBD and 1.5% Δ9-THC) vs. placebo in patients diagnosed with Autism Spectrum Disorder. The trial will contain two phases in which patients will first receive a twelve-week treatment of either cannabis or placebo followed by four weeks wash out period and another twelve weeks of crossover in the trial arms.

NCT ID: NCT04600882 Withdrawn - Clinical trials for Autism Spectrum Disorder

Characterization of a Clinical Subpopulation in Children With Autism Spectrum Disorder

Start date: November 30, 2020
Phase:
Study type: Observational

This single-center, observational study is being conducted to identify a well-characterized subgroup within the ASD patient population, based on clinical symptoms and biosample analysis.

NCT ID: NCT04186364 Withdrawn - Clinical trials for Autism Spectrum Disorder

Autism Spectrum Ambassador Program (ASAP) in the ED

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The investigators are evaluating the implementation and the effectiveness of a medical student staffed support program (ASAP) for children diagnosed with Autism Spectrum Disorder coming into Penn State Hershey Children's Hospital Emergency Department. The ASAP program involves training and assigning a medical student as an Ambassador to help advocate for the special needs of a child with ASD. This study is designed to compare patient satisfaction of children and families who are assigned an Ambassador to those who are not assigned an Ambassador during their time in the Emergency Department. The secondary objectives are to measure overall medical student satisfaction with the program, medical student career interests before and after participation, and medical student comfort level interacting with children with ASD before and after participation.

NCT ID: NCT03829878 Withdrawn - Clinical trials for Autism Spectrum Disorder

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

SPROUT
Start date: May 2020
Phase: Phase 2
Study type: Interventional

Adolescent autism spectrum disorder subjects with associated GI symptoms will be randomized to receive oral dosing of CP101 capsules in Treatment Group I or matching placebo capsules in Treatment Group II. The purpose of this study is to demonstrate the safety and effectiveness of CP101 in subjects with ASD and associated GI symptoms.

NCT ID: NCT03625999 Withdrawn - Clinical trials for Autism Spectrum Disorder

A Novel Intervention for Training Auditory Attention in Adolescents With Autism Spectrum Disorder

Start date: August 1, 2021
Phase: N/A
Study type: Interventional

Background: Previous research has shown that individuals with ASD often have difficulties coping with auditory stimuli in the environment. These difficulties can be extremely debilitating, lead to anxiety and disruptive behaviors, and interfere with the ability to process and understand speech. Research Design: In previous research, the investigators have identified a brain marker associated with poor auditory attention that can provide a direct readout of auditory processing issues. The investigators will develop and test a cognitive/behavioral intervention (a tablet-based game app) that is highly engaging and accessible to a wide range of individuals with ASD. The intervention is designed to train adolescents with ASD to adapt and attend to auditory cues. Objectives: To evaluate whether the intervention leads to improvement in auditory attention as assessed by behavior changes over the course of training; to investigate the impact of the intervention on behavioral assessment of problems hearing speech in noisy environments, neural processing of sounds, and changes in parent report on responses to sounds that impact that daily lives of the participants; and finally- to determine which adolescents with ASD benefit the most and least from interventions such as this one. We hypothesize that we can elicit changes in the neural processing of sounds for adolescents with ASD via training in the form of the tablet-based game we are developing. If we are successful, this could lead to other interventions for persons with ASD in the hopes of improving the auditory difficulties they face.

NCT ID: NCT03489811 Withdrawn - Anxiety Clinical Trials

The Effect of Aroma on Anxiety Among Children With Autism.

Start date: July 24, 2019
Phase: N/A
Study type: Interventional

This study evaluates the effects of essential oils on anxiety scores among children who have an autism spectrum disorder. One third of the children will receive a control blend of oils, one third of the children will receive a test blend of oils, and the other third will receive a second test blend of oils.

NCT ID: NCT02947880 Withdrawn - Autistic Disorder Clinical Trials

Evaluation of the Efficiency of Treatment by BUMETANIDE on Autistic Children With a Known Ethiology

BUMAUTEP
Start date: December 2016
Phase: Phase 2
Study type: Interventional

During a previous therapeutic trial, investigators showed that the bumetanide improved significantly autism. This trial showed that a therapeutic response was obtained in 75% of cases. These first results were reinforced by a study led with adult patients for whom the eye tracking measurements as well as the functional MRI showed a diminution of the response time and a modification (amplification) of the cerebral response during an emotions recognition test. Finally, investigators confirmed the physiological mechanism behind the action of the bumetanide in a study in two mouse models of autism.

NCT ID: NCT02945423 Withdrawn - Autistic Disorder Clinical Trials

Improving the Understanding of Catatonia in Autism

A-CAT
Start date: March 2020
Phase:
Study type: Observational

Catatonia is a neuropsychiatric syndrome which is frequently missed or misdiagnosed among psychiatric patients. The current project is a systematic examination of catatonia which will characterize the phenotype and identify biological correlates that play a central role in the pathophysiology and effective pharmacological treatment of this condition.